Barrett Esophagus.
Aged
Barrett Esophagus
/ diagnosis
Biopsy, Needle
Cell Transformation, Neoplastic
/ pathology
Early Detection of Cancer
/ methods
Endoscopy
/ methods
Esophagoscopy
/ methods
Female
Humans
Immunohistochemistry
Incidence
Male
Middle Aged
Precancerous Conditions
/ pathology
Prognosis
Risk Assessment
Treatment Outcome
Journal
Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
05
07
2018
revised:
17
12
2018
accepted:
30
01
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
14
1
2020
Statut:
ppublish
Résumé
Barrett esophagus is a metaplastic change in the lining of the distal esophageal epithelium, characterized by replacement of the normal squamous epithelium by specialized intestinal metaplasia. The presence of Barrett esophagus increases the risk of esophageal adenocarcinoma several-fold. Esophageal adenocarcinoma is a malignancy with rapidly rising incidence and persistently poor outcomes when diagnosed after the onset of symptoms. Risk factors for Barrett esophagus include chronic gastroesophageal reflux, central obesity, white race, male gender, older age, smoking, and a family history of Barrett esophagus or esophageal adenocarcinoma. Screening for Barrett esophagus in those with several risk factors followed by endoscopic surveillance to detect dysplasia or adenocarcinoma is currently recommended by society guidelines. Minimally invasive nonendoscopic tools for the early detection of Barrett esophagus are currently being developed. Multimodality endoscopic therapy-using a combination of endoscopic resection and ablation techniques-for the treatment of dysplasia and early adenocarcinoma is successful in eliminating intestinal metaplasia and preventing progression to adenocarcinoma, with outcomes comparable to those after esophagectomy. Risk stratification of those diagnosed with Barrett esophagus is a challenge at present, with active research focused on identifying clinical and biomarker panels to identify those with low and high risk of progression. This narrative review highlights some of the challenges and recent progress in this field.
Identifiants
pubmed: 31486383
pii: S0025-6196(19)30124-7
doi: 10.1016/j.mayocp.2019.01.032
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1888-1901Informations de copyright
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.